Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage

Circulation

Volumn 111, Issue 23, 2005, Pages 3087-3094

  Fiebeler, Anette ^a,g   Nussberger, Jürg ^e   Shagdarsuren, Erdenechimeg ^a   Rong, Song ^c   Hilfenhaus, Georg ^a   Al Saadi, Nidal ^a   Dechend, Ralf ^a   Wellner, Maren ^a   Meiners, Silke ^a   Maser Gluth, Christiane ^f   Jeng, Arco Y ^d   Webb, Randy L ^d   Luft, Friedrich C ^a,b   Muller, Dominik N ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Aldosterone; Angiotensin; Heart failure; Inflammation; Renin

Indexed keywords

4 (5,6,7,8 TETRAHYDROIMIDAZO [1,5 A]PYRIDIN 5 YL)BENZONITRILE; ALDOSTERONE; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN; ANGIOTENSINOGEN; CORTICOSTERONE; DEXAMETHASONE; ENZYME INHIBITOR; FAD 286; LOSARTAN; RENIN; UNCLASSIFIED DRUG;

ADRENAL GLAND; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL INFILTRATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; GENE OVEREXPRESSION; HEART; HEART INJURY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY; KIDNEY INJURY; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; RAT; TRANSGENIC ANIMAL;

ADRENAL GLANDS; ADRENALECTOMY; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ENZYME INHIBITORS; FIBROSIS; HEART DISEASES; HUMANS; INFLAMMATION; KIDNEY DISEASES; LOSARTAN; MYOCARDIUM; RATS; RENIN;

EID: 20544453256     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.521625     Document Type: Article

References (35)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol. 2004;217:75-79.
4. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
5. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41: 64-68.
6. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M. Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
7. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002; 161:1679-1693.
8. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension. 1999:33:212-218.
9. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
10. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappaB activation in angiotensin II-induced cardiac injury. Hypertension. 2001;37:787-793.
11. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U, Kaling M, Bachmann S, Fukamizu A, Mullins JJ, Murakami K. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A. 1992;89:7806-7810.
12. Nussberger J, Waeber B, Brunner HR, Burris JF, Vetter W. Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. J Lab Clin Med. 1984;104:789-796.
13. Poulsen K, Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab. 1974;39:816-825.
14. Vecsei P. Glucocorticoids: cortisol, corticosterone, compound S and their metabolites. In: Jaffe BM, Behrmann HR, eds. Methods of Hormone Radioimmunoassays. New York, NY: Academic Press; 1979:767-796.
15. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143: 4828-4836.
16. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension. 2004;44:340-345.
17. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955-963.
18. Schiffrin EL, Thome FS, Genest J. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats. Hypertension. 1983;5:V16-V21.
19. Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyahara K, Miura S, Ohnishi T, Ichikawa Y, Nakao K, Imura H, Ulick S, Shizuta Y. Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA. 1992;89:1458-1462.
20. Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z, Stratakis CA. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab. 1998;83:1033-1036.
21. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology. 2000;141:1901-1904.
22. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997;138:3369-3373.
23. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT Jr. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003;14:1990-1997.
24. Volpe M, Rubattu S, Ganten D, Enea I, Russo R, Lembo G, Mirante A, Condorelli G, Trimarco B. Dietary salt excess unmasks blunted aldosterone suppression and sodium retention in the stroke-prone phenotype of the spontaneously hypertensive rat. J Hypertens. 1993;11:793-798.
25. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Mabuchi H, Takeda R. Vascular aldosterone in genetically hypertensive rats. Hypertension. 1997;29:45-48.
26. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796-4802.
27. Davies E, MacKenzie SM. Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol. 2003;30:437-445.
28. Funder JW. Cardiac synthesis of aldosterone: going, going, gone? Endocrinology. 2004;145:4793-4795.
29. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat; physiological regulation. J Biol Chem. 1998;273:4883-4891.
30. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
31. Tsutamoto T, Wada A, Maeda K, Hayashi M, Tsutsui T, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Ishii C. Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. J Cardiovasc Pharmacol. 2003;41(suppl 1):S19-S22.
32. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Matsui T, Fujii M, Matsumoto T, Yamamoto T, Horie H, Ohnishi M, Kinoshita M. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2001;38:1375-1382.
33. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284-1291.
34. Krug AW, Schuster C, Gassner B, Freudinger R, Mildenberger S, Troppmair J, Gekle M. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem. 2002;277:45892-45897.
35. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99: 2694-2701.